Local NewsBusiness DUBLIN–(BUSINESS WIRE)–Jan 29, 2021– The “Global Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), End-user (Lab, PoC, Academia), and Region – Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%. The growth in the cardiac marker testing market is majorly driven by the growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent. The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation. Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment. Troponin I and T estimated to be the fastest-growing market Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality. The Asia-Pacific market to grow at the highest CAGR during the forecast period The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Asia-Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia-Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia-Pacific countries. Market Dynamics DriversGrowing Incidence of Cardiovascular DiseasesRapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases WorldwideGrowing Funding from Public and Private Organizations for Research on Cardiac BiomarkersOngoing Clinical Trials for the Identification of Novel Cardiac Biomarkers RestraintsTechnical Problems Related to Sample Collection and StorageIssues Related to Regulatory and Reimbursement Systems OpportunitiesPoint-Of-Care Testing (POCT) with Cardiac BiomarkersOngoing Research on Novel Cardiac Biomarkers for Cardiovascular DiseasesEmerging Markets to Offer High-Growth Opportunities for Market Players Companies MentionedAbbott LaboratoriesBecton, Dickinson and CompanyBio-Rad Laboratories, Inc.bioMerieux SADanaher CorporationDiasorinF. Hoffmann-La Roche AGGuangzhou Wondfo Biotech Co. Ltd.LSI Medience CorporationOrtho Clinical DiagnosticsPerkinelmer, Inc.Randox LaboratoriesSiemens Healthineers AGThermo Fisher ScientificTosoh Corporation For more information about this report visit https://www.researchandmarkets.com/r/ebz4jq View source version on businesswire.com:https://www.businesswire.com/news/home/20210129005296/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES CARDIOLOGY SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 01/29/2021 08:00 AM/DISC: 01/29/2021 08:01 AM http://www.businesswire.com/news/home/20210129005296/en By Digital AIM Web Support – January 29, 2021 The Worldwide Cardiac Marker Testing Industry is Expected to Reach $5.5 Billion by 2025 – ResearchAndMarkets.com Twitter WhatsApp WhatsApp TAGS Facebook Pinterest Twitter Facebook Pinterest Previous articleWorldwide Smart Parking Competitive Analysis Report 2021 Featuring Robert Bosch, Continental, Aisin Seiki, Valeo, Siemens, Xerox, and Cubic – ResearchAndMarkets.comNext articlePuma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 Digital AIM Web Support
Before it was a set aside for posterity as one of the nation’s first national parks, the land within what is now Great Smoky Mountains National Park was home to thriving communities of Southern Appalachian highlanders.Now, that long-ago history is being detailed in an intriguing way by local author Gail Palmer, who’s new book “Cemeteries of the Smokies” was just published by the Great Smoky Mountains Association.In addition to a genuine chronicling of Appalachian lore and legend, the book serves as an extensive graveyard guidebook, listing nearly 5,000 graves along with their GPS coordinates, spread out across more than 150 graveyards within the park. There’s also a 96-page list of graves that were relocated before the flooding initiated by the construction of Fontana Dam in the 1940’s.Learn more about Palmer’s book here.